Drug intelligence / Profile preview

immune suppressive human adipose-derived mesenchymal stem cells + hematopoietic stem cells

Development stage: Preclinical
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous, Intrathecal, Intracerebroventricular

Overview

This is a combination cell therapy consisting of immune suppressive human adipose-derived mesenchymal stem cells (hAD-MSCs) and hematopoietic stem cells (HSCs). Mesenchymal stem/stromal cells are multipotent stromal cells derived from adipose tissue that possess immunomodulatory properties, including the ability to attenuate inflammation by modulating both innate and adaptive immune responses. Hematopoietic stem cells are responsible for the generation of all blood cell lineages and play a key role in reconstituting the hematopoietic system following injury or transplantation. The combination aims to leverage the immunosuppressive effects of hAD-MSCs with the regenerative capacity of HSCs, potentially enhancing therapeutic outcomes in conditions characterized by excessive inflammation or immune dysregulation. This approach is under investigation for various indications, including traumatic brain injury and other inflammatory or degenerative diseases[1].

Other names: immune suppressive human adipose-derived mesenchymal stem cells and hematopoietic stem cellsimmunosuppressive hAD-MSCs + HSCs

Targets

CXCR4 (C-X-C motif chemokine receptor 4)

Beyond the preview

Go deeper on immune suppressive human adipose-derived mesenchymal stem cells + hematopoietic stem cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on immune suppressive human adipose-derived mesenchymal stem cells + hematopoietic stem cells.

Explore the full profile